Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer



Status:Active, not recruiting
Conditions:Ovarian Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:4/6/2019
Start Date:June 29, 2015

Use our guide to learn which trials are right for you!

Phase II Randomized Trial of Nivolumab With or Without Ipilimumab in Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer

This randomized phase II trial studies how well nivolumab works with or without ipilimumab in
treating patients with epithelial ovarian, primary peritoneal, or fallopian tube cancer that
has not responded after prior treatment (persistent) or has come back (recurrent).
Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the
body's immune system attack the cancer, and may interfere with the ability of tumor cells to
grow and spread.

PRIMARY OBJECTIVES:

I. To estimate the proportion of patients who have objective tumor response (complete or
partial) by modified Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 in patients
with persistent or recurrent epithelial ovarian, fallopian tube, primary peritoneal cancers,
treated with nivolumab or the combination of nivolumab and ipilimumab and to assess the
difference in objective response rate (ORR) between patients treated with nivolumab versus
those treated with the combination of nivolumab and ipilimumab.

SECONDARY OBJECTIVES:

I. To estimate the progression-free survival (PFS) hazard ratio for patients treated with
nivolumab versus those treated with the combination of nivolumab and ipilimumab.

II. To estimate and compare the duration of overall survival (OS) for patients treated with
nivolumab or the combination of nivolumab and ipilimumab.

III. To determine the frequency and severity of adverse events associated with treatment with
nivolumab or the combination of nivolumab and ipilimumab as assessed by Common Terminology
Criteria for Adverse Events (CTCAE).

IV. To determine whether cellular and molecular laboratory parameters in pre-treatment tissue
and peripheral blood specimens predict overall survival (OS), tumor response by modified
RECIST 1.1, and progression-free survival (PFS): PD-L1 expression in tumor cells and
tumor-infiltrating lymphocytes (TILs) measured by quantitative immunohistochemistry (IHC);
natural anti-tumor immunity in tumor cells and TILs measured using IHC and T cell repertoire
analyses; tumor "immunogenicity" as determined by the neo-epitope landscape using
next-generation whole exome sequencing (NGS); anti-tumor immune response in peripheral blood,
including serologic responses and analysis of T cell receptor (TCR) repertoires by deep
sequencing; and shift in quantitative laboratory peripheral blood parameters after the first
6 and 12 weeks of therapy.

OUTLINE: Patients are randomized to 1 of 2 treatment groups.

GROUP I:

INDUCTION: Patients receive nivolumab intravenously (IV) over 30 minutes every 2 weeks.
Treatment repeats every 4 weeks for 2 cycles in the absence of disease progression or
unacceptable toxicity.

MAINTENANCE: Patients receive nivolumab IV over 30 minutes every 2 weeks. Treatment repeats
every 4 weeks for up to 21 cycles in the absence of disease progression or unacceptable
toxicity.

GROUP II:

INDUCTION: Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 90 minutes.
Treatment repeats every 3 weeks for 4 cycles in the absence of disease progression or
unacceptable toxicity.

MAINTENANCE: Patients receive nivolumab IV over 30 minutes every 2 weeks. Treatment repeats
every 4 weeks for up to 21 cycles in the absence of disease progression or unacceptable
toxicity.

After completion of study treatment, patients are followed up for 100 days, every 3 months
for 2 years, and then every 6 months for 3 years.

Inclusion Criteria:

- Patients must have recurrent or persistent epithelial ovarian, fallopian tube, or
primary peritoneal cancer with documented disease progression (disease not amendable
to curative therapy); histologic confirmation of the original primary tumor is
required via the pathology report; NOTE: patients with mucinous histology are NOT
eligible; patients with carcinosarcoma histology are NOT eligible

- All patients must have measurable disease as defined by RECIST 1.1; measurable disease
is defined as at least one lesion that can be accurately measured in at least one
dimension (longest diameter to be recorded); each lesion must be >= 10 mm when
measured by computed tomography (CT), magnetic resonance imaging (MRI) or caliper
measurement by clinical exam; or >= 20 mm when measured by chest x-ray; lymph nodes
must be >= 15 mm in short axis when measured by CT or MRI

- Patients must have at least one "target" lesion to be used to assess response on this
protocol as defined by RECIST 1.1; tumors within a previously irradiated field will be
designated as "non-target" lesions unless progression is documented or a biopsy is
obtained to confirm persistence at least 90 days following completion of radiation
therapy

- Appropriate for study entry based on the following diagnostic workup:

- History/physical examination within 28 days prior to registration

- Imaging of target lesion(s) within 28 days prior to registration

- Further protocol-specific assessments:

- Recovery from effects of recent surgery, radiotherapy or chemotherapy

- Free of active infection requiring antibiotics (with the exception of
uncomplicated urinary tract infection [UTI])

- Any hormonal therapy directed at the malignant tumor must be discontinued at
least one week prior to registration

- Any other prior therapy directed at the malignant tumor including
chemotherapy, targeted agents, immunologic agents, and any investigational
agents, must be discontinued at least 4 weeks prior to registration (6 weeks
for nitrosoureas or mitomycin C)

- Any prior radiation therapy must be completed at least 4 weeks prior to
registration

- At least 4 weeks must have elapsed since major surgery

- Patients are allowed to have received up to three prior cytotoxic regimens for
treatment of their epithelial ovarian, fallopian tube, or primary peritoneal cancer;
they must have had one prior platinum-based chemotherapeutic regimen for management of
primary disease, possibly including intra-peritoneal therapy, consolidation,
biologic/targeted (non-cytotoxic) agents or extended therapy
(maintenance/consolidation) administered after surgical or non-surgical assessment;
patients are allowed to have received, but are not required to have received, one to
two cytotoxic regimens for management of recurrent or persistent disease; (for the
purposes of this study poly adenosine diphosphate [ADP] ribose polymerase [PARP]
inhibitors given for recurrent or progressive disease will be considered cytotoxic;
PARP inhibitors given as maintenance therapy in continuation with management of
primary disease will not be considered as a separate cytotoxic regimen); if two
cytotoxic regimens had been received for management of recurrent or persistent
disease, one of these regimens would have had to contain either a platinum or a taxane
agent

- Performance status of 0, 1 or 2 within 28 days prior to registration

- Absolute neutrophil count (ANC) >= 1,500/ul (within 14 days prior to registration)

- Platelets >= 100,000/ul (within 14 days prior to registration)

- Creatinine =< 1.5 x institutional/laboratory upper limit of normal (ULN) (within 14
days prior to registration)

- Bilirubin =< 1.5 x ULN; for patients with Gilbert's syndrome, bilirubin =< 3.0 mg/dL
is acceptable (within 14 days prior to registration)

- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN (within
14 days prior to registration)

- Albumin >= 2.8 g/dL (within 14 days prior to registration)

- Adequate thyroid function within 28 days prior to registration defined as serum
thyroid-stimulating hormone (TSH) in normal range

- The patient or a legally authorized representative must provide study-specific
informed consent prior to study entry

- Platinum-free interval (PFI) - patients must have progressed < 12 months after
completion of their last platinum-based chemotherapy; the date (platinum free
interval) should be calculated from the last administered dose of platinum therapy to
documentation of progression

- Adequate oxygen saturation via pulse oximeter within 28 days prior to registration
(i.e., patient can NOT have CTCAE hypoxia grade 2 or greater)

- Left ventricular ejection fraction (LVEF) >= 50% (measured within 28 days of study
entry)

Exclusion Criteria:

- Patients who have had prior therapy with nivolumab or with an anti-programmed cell
death (PD)-1, anti-PD-ligand (L)1, anti-PD-L2, anti-cytotoxic T-lymphocyte-antigen
(CTLA)-4 antibody, or any other antibody or drug specifically targeting T-cell
co-stimulation or immune check point pathways

- History of severe hypersensitivity reaction to any monoclonal antibody

- Patients with a history of other invasive malignancies, with the exception of
non-melanoma skin cancer and other specific malignancies are excluded if there is any
evidence of other malignancy being present within the last three years (2 years for
breast cancer); patients are also excluded if their previous cancer treatment
contraindicates this protocol therapy

- Patients who have received prior chemotherapy for any abdominal or pelvic tumor OTHER
THAN for the treatment of ovarian, fallopian tube, or primary peritoneal cancer within
the last three years are excluded; patients may have received prior adjuvant
chemotherapy and radiotherapy for localized breast cancer, provided that it was
completed more than 2 years prior to registration, and the patient remains free of
recurrent or metastatic disease and hormonal therapy has been discontinued; patients
who have received prior radiotherapy to any portion of the abdominal cavity or pelvis
or thoracic cavity within the last three years are excluded; prior radiation for
localized cancer of the head and neck or skin is permitted, provided that it was
completed more than three years prior to registration, and the patient remains free of
recurrent or metastatic disease

- Patients with uncontrolled illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure and unstable angina pectoris

- Patients with history of organ transplant

- Patients who are pregnant or nursing; women of child-bearing potential (WOCBP) must
agree to use adequate contraception (hormonal or barrier method of birth control;
abstinence) prior to study entry and for the duration of study participation; WOCBP
should use an adequate method to avoid pregnancy for 23 weeks after the last dose of
investigational drug; WOCBP must have a negative serum or urine pregnancy test
(minimum sensitivity 25 IV/L or equivalent units of human chorionic gonadotropin
[HCG]) within 24 hours prior to the start of nivolumab or nivolumab + ipilimumab;
women must not be breastfeeding; women who are not of childbearing potential (i.e.,
who are postmenopausal or surgically sterile) do not require contraception; women of
childbearing potential (WOCBP) is defined as any female who has experienced menarche
and who has not undergone surgical sterilization (hysterectomy and/or bilateral
oophorectomy) or who is not postmenopausal; menopause is defined clinically as 12
month amenorrhea in a woman over 45 in the absence of other biological or
physiological causes; in addition, women under the age of 55 must have a documented
serum follicle stimulating hormone (FSH) level greater than 40 mIU/mL; if, following
initiation of the investigational product(s), it is subsequently discovered that a
study subject is pregnant or may have been pregnant at the time of investigational
product exposure, including during at least 6 half-lives after product administration,
the investigational product will be permanently discontinued in an appropriate manner
(e.g., dose tapering if necessary for subject safety); the investigator must report
this event and any outcomes by amendment through Cancer Therapy Evaluation Program
(CTEP)-Adverse Event Reporting System (AERS); protocol-required procedures for study
discontinuation and follow-up must be performed on the subject unless contraindicated
by pregnancy (e.g., X-ray studies); other appropriate pregnancy follow-up procedures
should be considered if indicated; in addition, the investigator must report and
follow-up on information regarding the course of the pregnancy, including perinatal
and neonatal outcome; infants should be followed for a minimum of 8 weeks

- History or evidence upon physical examination of central nervous system (CNS) disease,
including primary brain tumor, seizures which are not controlled with non-enzyme
inducing anticonvulsants, any brain metastases and/or epidural disease, or history of
cerebrovascular accident (cerebrovascular accident [CVA], stroke), transient ischemic
attack (TIA) or subarachnoid hemorrhage within six months prior to the first date of
study treatment

- In order for patients with known history of testing positive for human
immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) to be
eligible, they must be on a stable highly active antiretroviral therapy (HAART)
regimen, have cluster of differentiation (CD)4 counts > 350, with no detectable viral
load on quantitative polymerase chain reaction (PCR)

- Patients with treated hepatitis virus infections (hepatitis B or hepatitis C) are
eligible if they have been definitively treated for 6 months, have no detectable viral
load on quantitative PCR, and liver function tests (LFTs) meet eligibility
requirements

- Patients with active autoimmune disease or history of autoimmune disease that might
recur, which may affect vital organ function or require immune suppressive treatment
including systemic corticosteroids, should be excluded; these include but are not
limited to patients with a history of immune related neurologic disease, multiple
sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia
gravis; systemic autoimmune disease such as systemic lupus erythematosus (SLE),
connective tissue diseases, scleroderma, inflammatory bowel disease, Crohn's,
ulcerative colitis, hepatitis; and patients with a history of toxic epidermal
necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome should be
excluded; patient with vitiligo, endocrine deficiencies including thyroiditis managed
with replacement hormones including physiologic corticosteroids are eligible; patients
with rheumatoid arthritis and other arthropathies, Sjogren's syndrome and psoriasis
controlled with topical medication and patients with positive serology, such as
antinuclear antibodies (ANA), anti-thyroid antibodies should be evaluated for the
presence of target organ involvement and potential need for systemic treatment but
should otherwise be eligible

- Patients are permitted to enroll if they have vitiligo, type I diabetes mellitus,
residual hypothyroidism due to autoimmune condition only requiring hormone replacement
(such as Hashimoto's thyroiditis), psoriasis not requiring systemic treatment, or
conditions not expected to recur in the absence of an external trigger (precipitating
event)

- Patients should be excluded if they have a condition requiring systemic treatment with
either corticosteroids (> 10 mg daily prednisone equivalents) or other
immunosuppressive medications within 14 days of study drug administration; inhaled or
topical steroids and adrenal replacement doses =< 10 mg daily prednisone equivalents
are permitted in the absence of active autoimmune disease; patients are permitted to
use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids
(with minimal systemic absorption); a brief course of corticosteroids for prophylaxis
(e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g.,
delayed-type hypersensitivity reaction caused by contact allergen) is permitted

- Any of the following within 2 months of registration: active peptic ulcer disease,
diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, malabsorption
syndrome; any of the following within 6 months of registration: intra-abdominal
abscess, gastrointestinal obstruction requiring parenteral hydration and/or nutrition,
gastrointestinal perforation; Note: complete resolution of an intra-abdominal abscess
must be confirmed prior to registration even if the abscess occurred more than 6
months prior to registration

- No planned concomitant, non-protocol directed anti-cancer therapy

- Grade >= 2 peripheral neuropathy
We found this trial at
206
sites
Louisville, Kentucky 40202
Principal Investigator: Mehmet S. Copur
Phone: 501-622-2100
?
mi
from
Louisville, KY
Click here to add this to my saved trials
800 Washington St
Boston, Massachusetts 02111
(617) 636-5000
Principal Investigator: Young B. Kim
Phone: 617-636-5000
Tufts Medical Center Tufts Medical Center is an internationally-respected academic medical center – a teaching...
?
mi
from
Boston, MA
Click here to add this to my saved trials
Bremerton, Washington 98310
?
mi
from
Bremerton, WA
Click here to add this to my saved trials
3300 Gallows Road
Falls Church, Virginia 22042
(703) 776-4001
Principal Investigator: Annette Bicher
Phone: 703-208-6650
Inova Fairfax Hospital Inova Fairfax Hospital, Inova's flagship hospital, is an 833-bed, nationally recognized regional...
?
mi
from
Falls Church, VA
Click here to add this to my saved trials
200 North Park Street
Kalamazoo, Michigan 49007
(269) 382-2500
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
West Michigan Cancer Center In 1994, Borgess Health Alliance and Bronson Healthcare Group opened the...
?
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
825 Eastlake Ave E
Seattle, Washington 98109
(206) 288-7222
Principal Investigator: Heidi J. Gray
Phone: 206-616-8289
Seattle Cancer Care Alliance Seattle Cancer Care Alliance (SCCA) is a cancer treatment center that...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
1200 Old York Road
Abington, Pennsylvania 19001
(215) 481–2000
Principal Investigator: Joel I. Sorosky
Phone: 215-481-2402
Abington Memorial Hospital Abington Memorial Hospital (AMH) is a 665-bed, regional referral center and teaching...
?
mi
from
Abington, PA
Click here to add this to my saved trials
1 Akron General Avenue
Akron, Ohio 44307
?
mi
from
Akron, OH
Click here to add this to my saved trials
Allentown, Pennsylvania 18103
Principal Investigator: Alyson F. McIntosh
Phone: 610-402-2273
?
mi
from
Allentown, PA
Click here to add this to my saved trials
364 White Oak St
Asheboro, North Carolina 27203
(336) 625-5151
Principal Investigator: Vinay K. Gudena
Phone: 336-832-0821
Randolph Hospital Since 1932, Randolph Hospital has been fortunate to employ dedicated and loyal personnel...
?
mi
from
Asheboro, NC
Click here to add this to my saved trials
Auburn, California 95602
Principal Investigator: Stacy D. D'Andre
Phone: 415-209-2686
?
mi
from
Auburn, CA
Click here to add this to my saved trials
Auburn, California 95603
Principal Investigator: Stacy D. D'Andre
Phone: 415-209-2686
?
mi
from
Auburn, CA
Click here to add this to my saved trials
Aurora, Colorado 80012
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
?
mi
from
Aurora, CO
Click here to add this to my saved trials
2000 Ogden Ave
Aurora, Illinois 60504
(630) 978-6200
Principal Investigator: Kendrith M. Rowland
Phone: 630-978-6212
Rush - Copley Medical Center Rush-Copley is proud to be the leading provider of health...
?
mi
from
Aurora, IL
Click here to add this to my saved trials
2401 W Belvedere Ave
Baltimore, Maryland 21215
(410) 601-9000
Principal Investigator: Abbie L. Fields
Phone: 410-601-6120
Sinai Hospital of Baltimore Sinai Hospital of Baltimore provides a broad array of high-quality, cost-effective...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
6701 N Charles St
Baltimore, Maryland 21204
(443) 849-2000
Principal Investigator: Paul Celano
Phone: 443-849-3706
Greater Baltimore Medical Center The 255-bed medical center (acute and sub-acute care) is located on...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
401 North Broadway
Baltimore, Maryland 21287
410-955-5000
Principal Investigator: Deborah K. Armstrong
Phone: 410-955-8804
Johns Hopkins University-Sidney Kimmel Cancer Center The name Johns Hopkins has become synonymous with excellence...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
4305 New Shepherdsville Road
Bardstown, Kentucky 40004
?
mi
from
Bardstown, KY
Click here to add this to my saved trials
Basking Ridge, New Jersey 07920
Principal Investigator: Dmitriy Zamarin
Phone: 212-639-7202
?
mi
from
Basking Ridge, NJ
Click here to add this to my saved trials
?
mi
from
Beachwood, OH
Click here to add this to my saved trials
Bemidji, Minnesota 56601
?
mi
from
Bemidji, MN
Click here to add this to my saved trials
Berkeley, California 94704
Principal Investigator: Stacy D. D'Andre
Phone: 415-209-2686
?
mi
from
Berkeley, CA
Click here to add this to my saved trials
Bethlehem, Pennsylvania 18015
Principal Investigator: Nicholas P. Taylor
Phone: 610-954-3582
?
mi
from
Bethlehem, PA
Click here to add this to my saved trials
300 N. Seventh St.
Bismarck, North Dakota 58501
(701) 323-6000
Principal Investigator: Maria C. Bell
Phone: 218-333-5000
Sanford Bismarck Medical Center Whether your stay in our hospital is one day for same...
?
mi
from
Bismarck, ND
Click here to add this to my saved trials
Bolivar, Missouri 65613
?
mi
from
Bolivar, MO
Click here to add this to my saved trials
1100 Balsam Ave
Boulder, Colorado 80304
(303) 440-2273
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Boulder Community Hospital Founded in 1922 as a community-owned and operated not-for-profit hospital, Boulder Community...
?
mi
from
Boulder, CO
Click here to add this to my saved trials
Boulder, Colorado 80303
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
?
mi
from
Boulder, CO
Click here to add this to my saved trials
Branson, Missouri 65616
?
mi
from
Branson, MO
Click here to add this to my saved trials
?
mi
from
Bremerton, WA
Click here to add this to my saved trials
Brownstown, Michigan 48183
?
mi
from
Brownstown, MI
Click here to add this to my saved trials
Burien, Washington 98166
?
mi
from
Burien, WA
Click here to add this to my saved trials
Burlington, North Carolina 27216
Principal Investigator: Vinay K. Gudena
Phone: 336-832-0821
?
mi
from
Burlington, NC
Click here to add this to my saved trials
Cameron Park, California 95682
Principal Investigator: Stacy D. D'Andre
Phone: 415-209-2686
?
mi
from
Cameron Park, CA
Click here to add this to my saved trials
Chattanooga, Tennessee 37404
?
mi
from
Chattanooga, TN
Click here to add this to my saved trials
5841 S Maryland Ave
Chicago, Illinois 60637
1-773-702-6180
Principal Investigator: John W. Moroney
Phone: 773-834-7424
University of Chicago Comprehensive Cancer Center The University of Chicago Comprehensive Cancer Center (UCCCC) is...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Cincinnati, Ohio 45242
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Cincinnati, Ohio 45220
Principal Investigator: Mehmet S. Copur
Phone: 501-622-2100
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Cincinnati, Ohio 45255
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Cincinnati, Ohio 45247
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
2049 E 100th St
Cleveland, Ohio 44106
(216) 444-2200
Principal Investigator: Peter G. Rose
Phone: 866-223-8100
Cleveland Clinic Foundation The Cleveland Clinic (formally known as The Cleveland Clinic Foundation) is a...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
10900 Euclid Ave
Cleveland, Ohio 44106
216-368-2000
Case Western Reserve Univ Continually ranked among America's best colleges, Case Western Reserve University has...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
18101 Lorain Avenue
Cleveland, Ohio 44111
216.476.7000
Principal Investigator: Peter G. Rose
Phone: 866-223-8100
Cleveland Clinic Cancer Center at Fairview Hospital Fairview Hospital is a 488-bed hospital located at...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Clinton Township, Michigan 48038
?
mi
from
Clinton Township, MI
Click here to add this to my saved trials
12495 University Ave
Clive, Iowa 50325
(515) 358-9700
Principal Investigator: Mehmet S. Copur
Phone: 501-622-2100
Mercy Cancer Center - West Lakes When it comes to cancer care, there
?
mi
from
Clive, IA
Click here to add this to my saved trials
Clive, Iowa 50325
Principal Investigator: Mehmet S. Copur
Phone: 501-622-2100
?
mi
from
Clive, IA
Click here to add this to my saved trials
6001 E Woodmen Rd
Colorado Springs, Colorado 80923
(719) 776-5000
Principal Investigator: Mehmet S. Copur
Phone: 501-622-2100
Penrose-Saint Francis Healthcare Founded by the Sisters of St. Francis and the Sisters of Charity,...
?
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Colorado Springs, Colorado 80907
Principal Investigator: Mehmet S. Copur
Phone: 501-622-2100
?
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
1400 East Boulder Street
Colorado Springs, Colorado 80909
?
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Commack, New York 11725
Principal Investigator: Dmitriy Zamarin
Phone: 212-639-7202
?
mi
from
Commack, NY
Click here to add this to my saved trials
Corbin, Kentucky 40701
?
mi
from
Corbin, KY
Click here to add this to my saved trials
Council Bluffs, Iowa 51503
Principal Investigator: Mehmet S. Copur
Phone: 501-622-2100
?
mi
from
Council Bluffs, IA
Click here to add this to my saved trials
5201 Harry Hines Blvd
Dallas, Texas 75235
(214) 590-8000
Principal Investigator: David S. Miller
Phone: 214-590-5582
Parkland Memorial Hospital As our community's public health system, Parkland is the foundation for a...
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Dallas, Texas 75390
Principal Investigator: David S. Miller
Phone: 214-590-5582
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Danville, Illinois 61832
Principal Investigator: Kendrith M. Rowland
Phone: 630-978-6212
?
mi
from
Danville, IL
Click here to add this to my saved trials
Davis, California 95616
Principal Investigator: Stacy D. D'Andre
Phone: 415-209-2686
?
mi
from
Davis, CA
Click here to add this to my saved trials
Dearborn, Michigan 48126
Principal Investigator: Thomas E. Buekers
Phone: 313-916-1784
?
mi
from
Dearborn, MI
Click here to add this to my saved trials
Decatur, Georgia 30033
Principal Investigator: Sharad A. Ghamande
Phone: 706-721-1663
?
mi
from
Decatur, GA
Click here to add this to my saved trials
777 Bannock St
Denver, Colorado 80204
(303) 436-6000
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Denver Health Medical Center Denver Health is a comprehensive, integrated organization providing level one care...
?
mi
from
Denver, CO
Click here to add this to my saved trials
4567 E 9th Ave
Denver, Colorado 80220
(303) 320-2121
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Rose Medical Center Well known as a Denver institution and a 9th Avenue landmark for...
?
mi
from
Denver, CO
Click here to add this to my saved trials
2525 S Downing St
Denver, Colorado 80210
(303) 778-1955
Principal Investigator: Mehmet S. Copur
Phone: 501-622-2100
Porter Adventist Hospital Founded in 1930, Porter Adventist Hospital has provided people throughout Denver and...
?
mi
from
Denver, CO
Click here to add this to my saved trials
1721 East 19th Ave., Suite #200 & #300
Denver, Colorado 80218
720-754-4800
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Colorado Blood Cancer Institute When patients come to the Colorado Blood Cancer Institute, the entire...
?
mi
from
Denver, CO
Click here to add this to my saved trials
Denver, Colorado 80218
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
?
mi
from
Denver, CO
Click here to add this to my saved trials
Denver, Colorado 80220
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
?
mi
from
Denver, CO
Click here to add this to my saved trials
Denver, Colorado 80218
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
?
mi
from
Denver, CO
Click here to add this to my saved trials
Denver, Colorado 80218
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
?
mi
from
Denver, CO
Click here to add this to my saved trials
1111 6th Ave
Des Moines, Iowa 50314
(515) 247-3121
Principal Investigator: Mehmet S. Copur
Phone: 501-622-2100
Mercy Medical Center - Des Moines Mercy Medical Center
?
mi
from
Des Moines, IA
Click here to add this to my saved trials
Des Moines, Iowa 50314
Principal Investigator: Mehmet S. Copur
Phone: 501-622-2100
?
mi
from
Des Moines, IA
Click here to add this to my saved trials
2799 W Grand Blvd
Detroit, Michigan 48202
(313) 916-2600
Principal Investigator: Thomas E. Buekers
Phone: 313-916-1784
Henry Ford Hospital Founded in 1915 by auto pioneer Henry Ford and now one of...
?
mi
from
Detroit, MI
Click here to add this to my saved trials
4160 John R St #2122
Detroit, Michigan 48201
(313) 833-1785
Principal Investigator: Robert T. Morris
Phone: 313-576-9363
Wayne State University/Karmanos Cancer Institute Karmanos is based in southeast Michigan, in midtown Detroit, and...
?
mi
from
Detroit, MI
Click here to add this to my saved trials
Dover, New Hampshire 03820
Principal Investigator: John O. Schorge
Phone: 877-726-5130
?
mi
from
Dover, NH
Click here to add this to my saved trials
Durango, Colorado 81301
Principal Investigator: Mehmet S. Copur
Phone: 501-622-2100
?
mi
from
Durango, CO
Click here to add this to my saved trials
Durango, Colorado 81301
Principal Investigator: Mehmet S. Copur
Phone: 501-622-2100
?
mi
from
Durango, CO
Click here to add this to my saved trials
Easley, South Carolina 29640
Principal Investigator: Jeffrey W. Elder
Phone: 864-679-3966
?
mi
from
Easley, SC
Click here to add this to my saved trials
Effingham, Illinois 62401
?
mi
from
Effingham, IL
Click here to add this to my saved trials
501 E. Hampden Ave.
Englewood, Colorado 80113
303-788-5000
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
?
mi
from
Englewood, CO
Click here to add this to my saved trials
Englewood, Colorado 80113
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
?
mi
from
Englewood, CO
Click here to add this to my saved trials
Enumclaw, Washington 98022
?
mi
from
Enumclaw, WA
Click here to add this to my saved trials
Fargo, North Dakota 58122
?
mi
from
Fargo, ND
Click here to add this to my saved trials
2601 Broadway
Fargo, North Dakota 58102
(701) 234-2900
Principal Investigator: Maria C. Bell
Phone: 218-333-5000
Sanford Clinic North-Fargo Sanford Health is an integrated health system headquartered in the Dakotas and...
?
mi
from
Fargo, ND
Click here to add this to my saved trials
801 Broadway North
Fargo, North Dakota 58122
Principal Investigator: Maria C. Bell
Phone: 218-333-5000
?
mi
from
Fargo, ND
Click here to add this to my saved trials
Federal Way, Washington 98003
?
mi
from
Federal Way, WA
Click here to add this to my saved trials
1024 S Lemay Ave
Fort Collins, Colorado 80524
(970) 495-7000
Principal Investigator: Kian Behbakht
Phone: 720-848-0650
Poudre Valley Hospital A 270-bed regional medical center offering a wide array of treatments, surgeries,...
?
mi
from
Fort Collins, CO
Click here to add this to my saved trials
Gaffney, South Carolina 29341
Principal Investigator: James E. Hunter
Phone: 800-486-5941
?
mi
from
Gaffney, SC
Click here to add this to my saved trials
Geneva, Illinois 60134
Principal Investigator: LaToya J. Perry
Phone: 630-315-1918
?
mi
from
Geneva, IL
Click here to add this to my saved trials
Golden, Colorado 80401
Principal Investigator: Mehmet S. Copur
Phone: 501-622-2100
?
mi
from
Golden, CO
Click here to add this to my saved trials
Golden, Colorado 80401
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
?
mi
from
Golden, CO
Click here to add this to my saved trials
Grand Island, Nebraska 68803
Principal Investigator: Mehmet S. Copur
Phone: 501-622-2100
?
mi
from
Grand Island, NE
Click here to add this to my saved trials
100 Michigan St NE
Grand Rapids, Michigan 49503
(616) 391-1774
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
Spectrum Health at Butterworth Campus Butterworth Hospital is one of four facilities that make up...
?
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
1801 16th St
Greeley, Colorado 80631
(970) 352-4121
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
North Colorado Medical Center NCMC is a fully accredited, private, non-profit facility licensed to operate...
?
mi
from
Greeley, CO
Click here to add this to my saved trials
501 N. Elam Avenue
Greensboro, North Carolina 27403
336-832-1100
Principal Investigator: Vinay K. Gudena
Phone: 336-832-0821
Cone Health Cancer Center Located adjacent to Wesley Long Hospital, our Cone Health Cancer Center...
?
mi
from
Greensboro, NC
Click here to add this to my saved trials
701 Grove Rd
Greenville, South Carolina 29605
(864) 455-7000
Principal Investigator: Jeffrey W. Elder
Phone: 864-679-3966
Greenville Memorial Hospital Greenville Memorial Medical Campus is a regional referral center for the diagnosis...
?
mi
from
Greenville, SC
Click here to add this to my saved trials
Greenville, South Carolina 29605
Principal Investigator: Jeffrey W. Elder
Phone: 864-679-3966
?
mi
from
Greenville, SC
Click here to add this to my saved trials
Greenville, South Carolina 29605
Principal Investigator: Jeffrey W. Elder
Phone: 864-679-3966
?
mi
from
Greenville, SC
Click here to add this to my saved trials
Greenville, South Carolina 29601
?
mi
from
Greenville, SC
Click here to add this to my saved trials
Greenville, South Carolina 29615
Principal Investigator: Jeffrey W. Elder
Phone: 864-679-3966
?
mi
from
Greenville, SC
Click here to add this to my saved trials
Greenville, South Carolina 29607
Principal Investigator: David Griffin
Phone: 800-486-5941
?
mi
from
Greenville, SC
Click here to add this to my saved trials
Greenwood Village, Colorado 80111
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
?
mi
from
Greenwood Village, CO
Click here to add this to my saved trials
Greer, South Carolina 29651
Principal Investigator: James E. Hunter
Phone: 800-486-5941
?
mi
from
Greer, SC
Click here to add this to my saved trials
Greer, South Carolina 29650
Principal Investigator: Jeffrey W. Elder
Phone: 864-679-3966
?
mi
from
Greer, SC
Click here to add this to my saved trials
500 Westchester Avenue
Harrison, New York 10604
Principal Investigator: Dmitriy Zamarin
Phone: 212-639-7202
?
mi
from
Harrison, NY
Click here to add this to my saved trials
Hendersonville, North Carolina 28971
?
mi
from
Hendersonville, NC
Click here to add this to my saved trials